Biomedical engineer Leyla Soleymani’s team was responsible for the hardware, including the chip that reads the sample.
Researchers at McMaster and Brock universities have created the prototype for a hand-held device to measure a biomarker for cancer, paving the way for home-based cancer monitoring and to improve access to diagnostic testing.
The device works much like the monitors that people with diabetes use to test their blood-sugar levels and could be used in a medical clinic or at home, all without lab work, greatly simplifying the process for testing blood for cancer’s signature.
A user would mix a droplet of blood in a vial of reactive liquid, then place the mixture onto a strip and insert it into a reader. In minutes, the device would measure an antigen that indicates the degree to which cancer is present.
The prototype has been designed to monitor prostate specific antigen (PSA) and the technology can readily be adapted to measure other markers, depending on the form of cancer or other chronic disease.
The ability to collect such information at home would make the daily lives of patients much easier while also generating accurate, shareable, up-to-the-minute results to guide their doctors in shaping care and treatment – all at a lower cost to the health-care system.
The device would also allow patients to continue to monitor their health after treatment.
The prototype was created by a research collaboration led by McMaster’s Leyla Soleymani, a biomedical engineer and Canada Research Chair in Miniaturized Biomedical Devices, and Brock’s Feng Li, an associate professor of chemistry who leads a bioanalytical chemistry lab.
Soleymani’s team (also including Sarah Traynor and Richa Pandey) was responsible for the hardware, including the chip that reads the sample, while Li’s team (also including Guan Wang) created the technology that analyzes the sample.
“This is another step toward truly personalized medicine,” Soleymani says. “We’re getting away from centralized, lab-based equipment for this kind of testing.
“This would make monitoring much more accessible and cut down on the number of times patients need to leave home to provide blood samples.”
Once commercialized, this device will be a paradigm shift for cancer diagnosis and prognosis, Li says.
“Since this device is a lot more accessible and user-friendly than conventional technologies, patients will be more willing to use it, which can improve clinical outcomes and save lives.”
The researchers’ proof-of-concept work is described in an article published in the journal Angewandte Chemie. The invention will need to be tested more broadly before earning the regulatory approvals that would permit commercial manufacturing
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Cancer biomarkers
- Microbiome researchers challenge the state of the art in colon cancer biomarker discovery
For the first time, researchers from VIB-KU Leuven, UZ Leuven, Janssen Pharmaceutica and multiple international collaborators have introduced quantitative methods and extensive confounder control to ...
- Q&A: Harnessing the power of the immune system to combat cancer
Currently, monoclonal antibodies targeting immune checkpoint proteins are a mainstay of cancer therapy and cancer drug development.
- Cancer Biomarkers Market Worth $42.0 billion | MarketsandMarkets
Cancer Biomarkers Market in terms of revenue was estimated to be worth $24.5 billion in 2024 and is poised to reach $42.0 billion by 2029, growing at ...
- Cancer Biomarkers Market Worth $42.0 billion | MarketsandMarkets™
Cancer Biomarkers Market in terms of revenue was estimated to be worth $24.5 billion in 2024 and is poised to reach $42.0 billion by 2029, growing at a CAGR of 11.3% from 2024 to 2029 according to a ...
- Prostate Cancer Breakthrough: Urine Test Avoids Unnecessary Biopsies
A study in JAMA Oncology reveals that MyProstateScore 2.0, a new urine test analyzing 18 genes, surpasses PSA in detecting significant prostate cancers and could reduce unnecessary biopsies by up to ...
Go deeper with Google Headlines on:
Cancer biomarkers
[google_news title=”” keyword=”cancer biomarkers” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Cancer biomarker detector
- New test reveals Cancer within minutes
ALBAWABA In a significant stride towards early cancer detection, researchers have developed an innovative AI-powered test capable of identifying three m ...
- mRNA Is Promising A Breakthrough In Fighting Cancer
When it comes to cancer, there’s innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all got acquainted with during the COVID-19 era as ...
- Cancer Biomarkers Market Worth $42.0 billion | MarketsandMarkets
Cancer Biomarkers Market in terms of revenue was estimated to be worth $24.5 billion in 2024 and is poised to reach $42.0 billion by 2029, growing at ...
- Cancer Biomarkers Market Worth $42.0 billion | MarketsandMarkets™
Cancer Biomarkers Market in terms of revenue was estimated to be worth $24.5 billion in 2024 and is poised to reach $42.0 billion by ...
- New blood test shows promise in early detection of ovarian cancer
A study reveals that glycoproteins in blood could be key biomarkers for early detection and staging of epithelial ovarian cancer, potentially allowing diagnosis through a simple blood test.
Go deeper with Google Headlines on:
Cancer biomarker detector
[google_news title=”” keyword=”cancer biomarker detector” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]